[Drug therapy of shock]

Area of Science:

• Physiology
• Pathology
• Pharmacology

Context:

• Shock is a complex syndrome characterized by clinical, hemodynamic, and metabolic derangements.
• Key features include clotting failure and disruptions in fluid, electrolyte, and acid-base balance.
• Effective management necessitates addressing hypovolemia, acidosis, and cardiovascular, pulmonary, and renal insufficiency.

Purpose:

• To define shock and outline essential management principles.
• To discuss the array of pharmacological agents available for treating shock.
• To highlight the significant mortality rates and common complications associated with specific shock types.

Summary:

• Shock is defined by clinical signs and measurable physiological changes, including hemodynamic instability, metabolic alterations, and coagulation defects.
• Treatment focuses on correcting hypovolemia, acidosis, and supporting failing organ systems (cardiovascular, pulmonary, renal).
• Despite therapeutic interventions, cardiogenic and gram-negative septic shock exhibit high mortality rates (over 80% and 30%, respectively), frequently complicated by acute lung injury or irreversible kidney damage.

Impact:

• Understanding shock's multifaceted nature is crucial for timely and effective clinical intervention.
• Highlights the urgent need for improved therapeutic strategies to reduce mortality in severe shock states.
• Emphasizes the importance of tailored treatment approaches for diverse etiologies of shock, such as fluid depletion, poisoning, and pancreatitis.